Advertisement

Infection

, Volume 46, Issue 6, pp 801–809 | Cite as

Subclinical Leishmania infection in patients with rheumatic diseases under biological drugs

  • Martina Maritati
  • Alessandro Trentini
  • Gregory Michel
  • Tiziana Bellini
  • Shawgi Almugadam
  • Stefania Hanau
  • Marcello Govoni
  • Pierre Marty
  • Carlo Contini
Original Paper
  • 92 Downloads

Abstract

Purpose

Climate changes and immunosuppression are influencing the spread of leishmaniasis and re-emergence in Northern Italy, respectively. We evaluated the prevalence of subclinical leishmaniasis in patients from a Northern Italian region with chronic inflammatory rheumatism (CIRD) receiving biological drugs (BD) and correlated it to the area of residence.

Methods

DNA from PBMC of patients affected by CIRD treated with either BD for at least 5 years (Group A) or other immunosuppressive drugs (Group B) was investigated by a qPCR for Leishmania infantum kDNA and compared to healthy subjects (Group C). Variables such as sex and age, rural areas, dog ownership, type of BD administered and association between BD and steroids, were evaluated by statistical analysis.

Results

A higher proportion of L. infantum DNA positivity was found in Group A than in Group C (p < 0.05), while no parasite DNA was detected in Group B. In Group A, 18/50 patients (36%) had higher rates of parasite DNA (from 1 to 136 to 1.000.000 copies/ml) than Group C (from 1 to 10 copies/ml). 14/18 (77.7%) of positive patients from Group A lived in rural areas, but no statistical differences occurred in relation to dog ownership or BD type (p < 0.0003).

Conclusions

We can speculate that exposure to rural areas appears to be a factor closely linked with the risk of developing Leishmania subclinical infection. A screening with molecular methods in patients with CIRD treated with BD living in these areas and monitoring Leishmania DNA during such therapies, would be mandatory to prevent delay in diagnosis should VL symptoms appear.

Keywords

Leishmania infantum Subclinical leishmaniasis Biologic drugs Rural areas Northern Italy Real-time PCR 

Abbreviations

VL

Visceral leishmaniasis

CL

Cutaneous leishmaniasis

CIRD

Chronic inflammatory rheumatic diseases

RA

Rheumatoid arthritis

PA

Psoriatic arthritis

AS

Ankylosing spondylitis

BD

Biological drugs

qPCR

Quantitative real-time PCR

Notes

Acknowledgements

Mahmoud Rachid for his help in molecular methods; Gianluca Rugna for having provided Leishmania strains and Sara Bonazza for her help in collecting PBMC specimens.

Author contribution

MM and CC equally contributed to the design of the study and the writing of the manuscript. MM CC and AT analysed and interpreted the patient’s data. GM and AT performed the statistical analysis. PM, SA, SH and TB contributed to the revision of the article. MG contributed to the collection of patient’s data. All authors read and approved the final version of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethics approval

The study was approved by the ethics committee of the University of Ferrara, Italy (protocol no. 150494).

Informed consent

Written informed consents were obtained from all participants before their enrolment.

Consent for publication

All the enrolled subjects had signed a written informed consent for publication.

Data availability

All the data included in the manuscript are available from the authors upon reasonable request.

References

  1. 1.
    Leishmaniasis - World Health Organization. Status Endemicity of cutaneous and visceral leishmaniasis worldwide. World Health Organization. 2018. http://www.who.int/news-room/fact-sheets/detail/leishmaniasis.
  2. 2.
    Moral L, Rubio EM, Moya M. A leishmanian skin test survey in the human population of l’ Alacantí region (Spain): implications for the epidemiology of Leishmania infantum infection in southern Europe. Trans R Soc Trop Med Hyg. 2002;96:129–32.CrossRefGoogle Scholar
  3. 3.
    Poeppl W, Herkner H, Tobudic S, Faas A, Auer H, Mooseder G, et al. Seroprevalence and asymptomatic carriage of Leishmania spp. in Austria, a non-endemic European country. Clin Microbiol Infect. 2013;19:572–7.CrossRefGoogle Scholar
  4. 4.
    Control of the leishmaniases: report of a meeting of the WHO Expert Commitee on the Control of Leishmaniases, Geneva, 22–26 March 2010. WHO technical report series 2010; n 949. Description. xiii, 1–186. http://apps.who.int/iris/bitstream/10665/44412/1/WHO_TRS_949_eng.pdf.
  5. 5.
    Ready PD. Biology of phlebotomine sandflies as vectors of disease agents. Annu Rev Entomol. 2013;58:227–50.CrossRefGoogle Scholar
  6. 6.
    Gradoni L. Pizzuti R, di Martino L, Gramiccia M, Pempinello R, Gaeta GB, Ferrara M, Scotti S, Altieri S. The epidemiology and surveillance of visceral leishmaniasis in the Campania region of Italy. The value of zymodeme typing. Epidemiol Infect. 1993;111:297–306.CrossRefGoogle Scholar
  7. 7.
    Varani S, Cagarelli R, Melchionda F, Attard L, Salvadori C, Finarelli AC, Gentilomi GA, et al. Ongoing outbreak of visceral leishmaniasis in Bologna Province, Italy, November 2012 to May 2013. Euro Surveill. 2013;18:20530.CrossRefGoogle Scholar
  8. 8.
    Leishmaniasis. Fact sheet. World Health Organization. Media Centre. http://www.who.int/mediacentre/factsheet/fs375/en/. Accessed Sep 2016
  9. 9.
    Xynos ID, Tektonidou MG, Pikazis D, Sipsas NV. Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe. Emerg Infect Dis. 2009;15:956–9.CrossRefGoogle Scholar
  10. 10.
    Zanger P, Kotter I, Kremsner PG, Gabrysch S. Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe. Clin Microbiol Infect. 2012;18:670–6.CrossRefGoogle Scholar
  11. 11.
    Martin-Mola E, Balsa A. Infectious complications of biologic agents. Rheum Dis Clin North Am. 2009;35:183–99.CrossRefGoogle Scholar
  12. 12.
    Srivastava P, Gidwani K, Picado A, Van der Auwera G, Tiwary P, et al. Molecular and serological markers of Leishmania donovani infection in healthy individuals from endemic areas of Bihar, India. Trop Med Int Health. 2013;18:548–54.CrossRefGoogle Scholar
  13. 13.
    Sakkas H, Gartzonika C, Levidiotou S. Laboratory diagnosis of human visceral leishmaniasis. J Vector Borne Dis. 2016;53:8–16.PubMedGoogle Scholar
  14. 14.
    le Fichoux Y, Quaranta JF, Aufeuvre JP, Lelievre A, Marty P, Suffia I, et al. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J Clin Microbiol. 1999;37:1953–7.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Riera C, Fisa R, Udina M, Gállego M, Portus M. Detection of Leishmania infantum cryptic infection in asymptomatic blood donors living in an endemic area (Eivissa, Balearic Islands, Spain) by different diagnostic methods. Trans R Soc Trop Med Hyg. 2004;98:102–10.CrossRefGoogle Scholar
  16. 16.
    Colomba C, Saporito L, Vitale F, Reale S, Vitale G, Casuccio A, et al. Cryptic Leishmania infantum infection in Italian HIV infected patients. BMC Infect Dis. 2009;9:199.CrossRefGoogle Scholar
  17. 17.
    Maritati M, Michel G, Almugadam S, Hanau S, Bellini T, Dallocchio F, et al. Real-time PCR to detect Leishmania Infantum DNA in immunocompetent patients with chronic inflammatory rheumatisms living in rural areas of Northern Italy and treated with biologic drugs (oral communication 0328). 26th ESCMID, Amsterdam, The Netherlands, 9–12 April 2016. ESCMID Library O328.Google Scholar
  18. 18.
    Contini C, Grilli A, Badia L, Guardigni V, Govoni M, Seraceni S. Detection of Chlamydophila pneumoniae in patients with arthritis: significance and diagnostic value. Rheumatol Int. 2011;31:1307–13.CrossRefGoogle Scholar
  19. 19.
    McCarthy-Burke C, Bates PA, Dwyer DM. Leishmania donovani: use of two different, commercially available, chemically defined media for the continuous in vitro cultivation of promastigotes. Exp Parasitol. 1991;73:385–7.CrossRefGoogle Scholar
  20. 20.
    Lachaud L, Chabbert E, Dubessay P, Dereure J, Lamothe J, Dedet JP, Bastien P. Value of two PCR methods for the diagnosis of canine visceral leishmaniasis and the detection of asymptomatic carriers. Parasitology. 2002;125:197–207.CrossRefGoogle Scholar
  21. 21.
    Dujardin JC, Campino L, Cañavate C, Dedet J-P, Gradoni L, Soteriadou K, et al. Spread of vector-borne diseases and neglect of Leishmaniasis, Europe. Emerg Infect Dis. 2008;14:1013–18.CrossRefGoogle Scholar
  22. 22.
    Mary C, Faraut F, Lascombe L, Dumon H. Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity. J Clin Microbiol. 2004;42:5249–55.CrossRefGoogle Scholar
  23. 23.
    Di Muccio T, Scalone A, Bruno A, Marangi M, Grande R, Armignacco O, Gradoni L, Gramiccia M. Epidemiology of imported leishmaniasis in Italy: implications for a European Endemic Country. Plos ONE. 2015;10:e0129418.CrossRefGoogle Scholar
  24. 24.
    Okwor I, Uzonna JE. The immunology of Leishmania/HIV coinfection. Immunol Res. 2013;56:163–71.CrossRefGoogle Scholar
  25. 25.
    Maroli M, Feliciangeli MD, Bichaud L, Charrel RN, Gradoni L. Phlebotomine sandflies and the spreading of leishmaniases and other diseases of public health concern. Med Vet Entomol. 2013;27:123–47.CrossRefGoogle Scholar
  26. 26.
    Signorini M, Cassini R, Drigo M, Frangipane di Regalbono A, Pietrobelli M, Montarsi F, Stensgaard AS. Ecological niche model of Phlebotomus perniciosus, the main vector of canine leishmaniasis in north-eastern Italy. Geospat Health. 2014;9:193–201.CrossRefGoogle Scholar
  27. 27.
    Maroli M, Rossi L, Baldelli R, Capelli G, Ferroglio E, Genchi C, Gramiccia M, Mortarino M, Pietrobelli M, Gradoni L. The north-ward spread of leishmaniasis in Italy: evidence from retrospective and on-going studies on the canine reservoir and phlebotomine vectors. Trop Med Int Health. 2008;13:256–64.CrossRefGoogle Scholar
  28. 28.
    van Griensven J, Carrillo E, Lopez-Velez R, Lynen L, Moreno J. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect. 2014;20:286–99.CrossRefGoogle Scholar
  29. 29.
    Marie I, Guglielmino E. Non tuberculous anti-TNF associated opportunistic infections. Rev Med Interne. 2010;31(5):353–60.CrossRefGoogle Scholar
  30. 30.
    Biglino A, Bolla C, Concialdi E, Trisciuoglio A, Romano A, Ferroglio E. Asymptomatic Leishmania infantum infection in an area of North Western Italy (Piedmont region) where such Infections are traditionally nonendemic. J Clin Microbiol. 2010;48:131–6.CrossRefGoogle Scholar
  31. 31.
    Echchakery M, Nieto J, Boussaa S, El Fajali N, Ortega S, Souhail K, Aajly H, Chicharro C, Carrillo E, Moreno J, Boumezzough A. Asymptomatic carriers of Leishmania infantum in patients infected with human immunodeficiency virus (HIV) in Morocco. Parasitol Res. 2018;117:1237–44.CrossRefGoogle Scholar
  32. 32.
    Mansueto P, Seidita A, Vitale G, Cascio A. Leishmaniasis in travelers: a literature review. Travel Med Infect Dis. 2014;12:563–81.CrossRefGoogle Scholar
  33. 33.
    Marty P, Lelievre A, Quaranta JF, Rahal A, Gari-Toussaint M, Le Fichoux Y. Use of the leishmanin skin test and western blot analysis for epidemiological studies in visceral leishmaniasis areas: experience in a highly endemic focus in Alpes-Maritimes (France). Trans R Soc Trop Med Hyg. 1994;88:658–9.CrossRefGoogle Scholar
  34. 34.
    Colomba C, Saporito L, Polara VF, Barone T, Corrao A, Titone L. Serological screening for Leishmania infantum in asymptomatic blood donors living in an endemic area (Sicily, Italy). Transfus Apher Sci. 2005;33:311–4.CrossRefGoogle Scholar
  35. 35.
    Pittalis S, Nicastri E, Spinazzola F, Ghirga P, De Marco M, Paglia MG, Narciso P. Leishmania infantum leishmaniasis in corticosteroid-treated patients. BMC Infect Dis. 2006;18:177.CrossRefGoogle Scholar
  36. 36.
    Pagliano P, Carannante N, Gramiccia M, Ascione T, Stornaiuolo G, Gradoni L, Faella FS, Gaeta GB. Visceral leishmaniasis causes fever and decompensation in patients with cirrhosis. Gut. 2007;56:893–4.CrossRefGoogle Scholar
  37. 37.
    Tordini G, Puttini C, Rossetti B, Sammarro G, Fanetti A, Cianchino S, et al. Which screening for Leishmania infantum in asymptomatic blood donors? Infez Med. 2011;19:152–6.PubMedGoogle Scholar
  38. 38.
    Jimenez-Marco T, Riera C, Girona-Llobera E, Guillen C, Iniesta L, Alcover M, et al. Strategies for reducing the risk of transfusion-transmitted leishmaniasis in an area endemic for Leishmania infantum: a patient- and donor-targeted approach. Blood Transfus. 2018;16:130–136.  https://doi.org/10.2450/2017.0201-16. Epub 2017 Mar 15.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Neumayr AL, Morizot G, Visser LG, Lockwood DN, Beck BR, Schneider S, Bellaud G, Cordoliani F, Foulet F, Laffitte EA, Buffet P, Blum JA. Clinical aspects and management of cutaneous leishmaniasis in rheumatoid patients treated with TNF-α antagonists. Travel Med Infect Dis. 2013;11:412–20.  https://doi.org/10.1016/j.tmaid.2013.05.003. (epub 2013 Aug 22).CrossRefPubMedGoogle Scholar
  40. 40.
    Kumar R, Pai K, Pathak K, Sundar S. Enzyme-linked immunosorbent assay for recombinant K39 antigen in diagnosis and prognosis of Indian visceral leishmaniasis. Clin Diagn Lab Immunol. 2001;8:1220–24.PubMedPubMedCentralGoogle Scholar
  41. 41.
    De Almeida Silva L, Romero HD, Prata A, Costa RT, Nascimento E, Carvalho SF, Rodrigues V. Immunologic tests in patients after clinical cure of visceral leishmaniasis. Am J Trop Med Hyg. 2006;75:739–43.CrossRefGoogle Scholar
  42. 42.
    Garcia-Garcia A, Martin-Sanchez J, Gallego M, Rivero-Roman A, Camacho A, Riera C, Morillas-Marquez F, Vergara S, Macias J, Pineda JA. Use of noninvasive markers to detect Leishmania infection in asymptomatic human immunodeficiency virus-infected patients. J Clin Microbiol. 2006;44:4455–58.CrossRefGoogle Scholar
  43. 43.
    Costa CHN, Pereira HF, Pereira FCA, Tavares JP, Araújo MV, Gonçalves MJO. Is the household dog a risk factor for American visceral leishmaniasis in Brazil. Trans R Soc Trop Med Hyg. 1999;93:464.CrossRefGoogle Scholar
  44. 44.
    Costa CHN, Gomes RBB, Silva MRB, Garcez LM, Ramos PKS, Santos RS, Shaw JJ, David JR, Maguire JH. Competence of the human host as a reservoir for Leishmania chagasi. J Infect Dis. 2000;182:997–1000.CrossRefGoogle Scholar
  45. 45.
    Gavgani ASM, Mohite H, Edrissian GH, Mohebali M, Clive RD. Domestic dog ownership in Iran is a risk factor for human infection with Leishmania infantum. Am J Trop Med Hyg. 2002;67:511–15.CrossRefGoogle Scholar
  46. 46.
    Jeziorski E, Dereure J, Mac Bullen G, Blanchet C, Ludwig C, Costes V, Rodière M. Mucosal relapse of visceral leishmaniasis in a child treated with anti-TNFα. Int J Infect Dis. 2015;33:135–6.CrossRefGoogle Scholar
  47. 47.
    Regione Emilia-Romagna: Progetto regionale di sorveglianza sulle malattie trasmesse da insetti vettori. Piano Regionale di controllo della leishmaniosi - anno 2014. http://www.anagrafecaninarer.it/acrer/Portals/0/normative/Relazione_Piano_Leishmania_2014%20senza%20tabelle%20canili.pdf.

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Section of Infectious Diseases and Dermatology, Department of Medical SciencesUniversity of FerraraFerraraItaly
  2. 2.Section of Medical Biochemistry, Molecular Biology and Genetics, Department of Biomedical and Specialist Surgical SciencesUniversity of FerraraFerraraItaly
  3. 3.INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Toxines Microbiennes dans la Relation Hôte–PathogènesNiceFrance
  4. 4.Faculté de MédecineUniversité de Nice Sophia AntipolisNiceFrance
  5. 5.Parasitologie-Mycologie, Centre Hospitalier Universitaire l’ArchetUniversité Côte d’AzurNiceFrance
  6. 6.Section of Hematology and Rheumatology, Department of Medical SciencesUniversity of FerraraFerraraItaly

Personalised recommendations